Education
About Us
Working with TipRanks
Follow Us
Mirum Pharmaceuticals (MIRM)
:MIRM
RESEARCH TOOLSreports
MIRM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$23.14 - $54.23
Previous CloseN/A
Volume92.82K
Average Volume (3M)551.88K
Market Cap
$2.33B
Enterprise Value$1.90B
Total Cash (Recent Filing)$51.96M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.71
Next Earnings
May 01, 2025EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.85
Shares Outstanding49,014,190
10 Day Avg. Volume647,624
30 Day Avg. Volume551,884
Standard Deviation0.16
R-Squared0.10
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.92
Price to Cash Flow (P/CF)-115.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit13.61
Enterprise Value/Ebitda-31.29
Forecast
1Y Price Target
$67.00Price Target Upside40.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Mirum Pharmaceuticals News
---
Bulls Say, Bears Say
Bulls Say
Regulatory ApprovalFDA approval of CTEXLI allows Mirum to market directly to patients with cerebrotendinous xanthomatosis, potentially increasing the number of diagnosed patients.
Revenue GrowthLivmarli net sales revenue showed significant growth, driven by its use in Alagille syndrome and progressive familial intrahepatic cholestasis.
Bears Say
Pipeline ChallengesTimelines for volixibat’s programs were reaffirmed, with enrollment completion for volixibat’s VISTAS trial in primary sclerosing cholangitis (PSC) expected in 2H25.
---
Ownership Overview
9.65% Insiders
26.31% Mutual Funds
41.45% Other Institutional Investors
10.30% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MIRM FAQ
What was Mirum Pharmaceuticals’s price range in the past 12 months?
Mirum Pharmaceuticals lowest stock price was $23.14 and its highest was $54.23 in the past 12 months.
What is Mirum Pharmaceuticals’s market cap?
Mirum Pharmaceuticals’s market cap is $2.33B.
When is Mirum Pharmaceuticals’s upcoming earnings report date?
Mirum Pharmaceuticals’s upcoming earnings report date is May 01, 2025 which is in 59 days.
How were Mirum Pharmaceuticals’s earnings last quarter?
Mirum Pharmaceuticals released its earnings results on Feb 26, 2025. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.258 by -$0.232.
Is Mirum Pharmaceuticals overvalued?
According to Wall Street analysts Mirum Pharmaceuticals’s price is currently Undervalued.
Does Mirum Pharmaceuticals pay dividends?
Mirum Pharmaceuticals does not currently pay dividends.
What is Mirum Pharmaceuticals’s EPS estimate?
Mirum Pharmaceuticals’s EPS estimate is -0.31.
How many shares outstanding does Mirum Pharmaceuticals have?
Mirum Pharmaceuticals has 49,014,190 shares outstanding.
What happened to Mirum Pharmaceuticals’s price movement after its last earnings report?
Mirum Pharmaceuticals reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.258. Following the earnings report the stock price went down -7.007%.
Which hedge fund is a major shareholder of Mirum Pharmaceuticals?
Currently, no hedge funds are holding shares in MIRM
---
Mirum Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$67.00 (40.85% Upside)
$67.00 (40.85% Upside)
Blogger Sentiment
Bullish
MIRM Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 73.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $971.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 5.1%
Last 30 Days ▲ 5.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
64.65%
12-Months-Change
Fundamentals
Return on Equity
-37.08%
Trailing 12-Months
Asset Growth
3.73%
Trailing 12-Months
Company Description
Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.
---
MIRM Company Deck
---
MIRM Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Mirum Pharmaceuticals demonstrated significant financial growth and strong pipeline advancements, with notable achievements including the approval of CTEXLI and the expansion of LIVMARLI's market. However, high operating expenses and challenges in fully penetrating the Alagille syndrome market were noted. The positive aspects of financial performance and pipeline progress outweigh the challenges, indicating a strong outlook for the company.Read More>---
MIRM Stock 12 Month Forecast
Average Price Target
$67.00
▲(40.85% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Novartis
―
Vertex Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering MIRM
1 Year
1 Year Success Rate
31/33 ratings generated profit
1 Year Average Return
+34.50%
reiterated a buy rating 5 days ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 93.94% of your transactions generating a profit, with an average return of +34.50% per trade.
---